IMPACT BIOMEDICAL INC IBO
ASignal's systematic analysis rates IBO as Bearish.
Reflects the latest available analysis · analyzed Nov 2, 2026
The case on IBO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Low P/E ratio (0.34x) indicating potential undervaluation
- Zero debt (debt-to-equity = 0.09x) suggesting strong balance sheet
- Positive free cash flow ($1.02M) despite negative operating cash flow
- High return on equity (23.46%) indicating efficient capital use
- Extremely high price-to-sales (927.60x) and EV/Revenue (1020.07x) multiples
- Negative operating margin (-23400.00%) signaling severe operational inefficiency
- Negative operating cash flow ($-508,000) and poor liquidity (current ratio = 0.16x)
- Declining revenue (YoY growth = -57.10%) and lack of earnings growth data
- Low news coverage with only 2 sources, limiting sentiment reliability
See the full verdict on IBO
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes IBO
Most investors never get a second opinion, let alone several. ASignal runs IBO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.